Comparative study on the therapeutic efficacy of topical bimatoprost (0.03%) ophthalmic solution and tacrolimus (0.1%) ointment in stable vitiligo.
Keywords:
Vitiligo, Bimatoprost, Tacrolimus, Topical therapy, RepigmentationAbstract
Background: Vitiligo is a chronic autoimmune skin disorder characterized by loss of melanocytes, leading to depigmented patches. Though not physically harmful, its appearance causes significant psychological distress, especially in darker-skinned individuals. Topical therapies like tacrolimus, calcineurin inhibitor, are first-line treatment for localized, stable vitiligo. However, bimatoprost, a prostaglandin analog known for its melanogenic properties, is emerging as a potential alternative. The current study was done to compare efficacy and safety of topical bimatoprost 0.03% solution versus tacrolimus 0.1% ointment in management of stable vitiligo.
Material & Methods: A randomized comparative study was conducted over 24 months in Department of Dermatology at Era’s Lucknow Medical College. Fifty clinically stable vitiligo patients (aged >18 years, <5% BSA involvement) were randomized into two groups: Group A received topical bimatoprost 0.03%, and Group B received topical tacrolimus 0.1%, both applied twice daily over lesions. Treatment was continued for 12 weeks, with follow-up every 4 weeks. Efficacy was assessed using the Vitiligo Area Scoring Index (VASI), Subjective score and Photographic documentation. Any side effects were documented at each follow-up.
Results: Both groups showed clinical improvement, with Group A demonstrating faster onset of repigmentation, particularly in facial lesions. Bimatoprost was well-tolerated with minimal side effects such as local hypertrichosis, while tacrolimus was associated with mild burning in some cases.
Conclusion: Topical bimatoprost 0.03% is a safe and effective alternative to tacrolimus 0.1% ointment in treating stable vitiligo, especially for cosmetically sensitive areas. Therefore, it can be considered as a treatment option in stable vitiligo.
References
Marchioro HZ, Silva de Castro CC, Fava VM, et al. Update on the pathogenesis of vitiligo. An Bras Dermatol. 2022;97(4):478–490. DOI:10.1016/j.abd.2021.09.002
Hu Z, Wang T. Beyond skin white spots: Vitiligo and associated comorbidities. Front Med (Lausanne). 2023;10:1072837. DOI:10.3389/fmed.2023.1072837
Zhang Y, Cai Y, Shi M, et al. The prevalence of vitiligo: A meta-analysis. PLoS One. 2016;11(9):e0163806. DOI:10.1371/journal.pone.0163806
Alikhan A, Felsten LM, Daly M, et al. Vitiligo: A comprehensive overview. Part I. J Am Acad Dermatol. 2011;65(3):473–491. DOI:10.1016/j.jaad.2010.11.061
Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo. Int J Dermatol. 2012;51(10):1206–1212. DOI:10.1111/j.1365-4632.2011.05377.x
Akl J, Lee S, Ju HJ, et al. Estimating the burden of vitiligo. Lancet Public Health. 2024;9(6):e386–e396. DOI:10.1016/S2468-2667(24)00064-4
Iacovelli P, Sinagra JL, Paro Vidolin A, et al. Relevance of thyroiditis in children with vitiligo. Dermatology. 2005;210(1):26–30. DOI:10.1159/000081484
Kartal D, Borlu M, Çınar SL, et al. Thyroid abnormalities in paediatric vitiligo. Postepy Dermatol Alergol. 2016;33(3):232–234. DOI:10.5114/ada.2016.60616
Njoo MD, Westerhof W. Vitiligo: Pathogenesis and treatment. Am J Clin Dermatol. 2001;2(3):167–181.
Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun. 2005;25(Suppl):63–68. DOI:10.1016/j.jaut.2005.09.001
Pathak GN, Tan IJ, Bai G, et al. Vitiligo: From mechanisms to treatable pathways. Skin Health Dis. 2024;4:e460. DOI:10.1002/ski2.460
Dellatorre G, Antelo DAP, Bedrikow RB, et al. Consensus on the treatment of vitiligo. An Bras Dermatol. 2020;95(Suppl 1):70–82. DOI:10.1016/j.abd.2020.03.011
Speeckaert R, van Geel N. Vitiligo: An update on pathophysiology and treatment options. Am J Clin Dermatol. 2017;18(6):733–744. DOI:10.1007/s40257-017-0293-7
Coondoo A, Phiske M, Verma S, et al. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014;5(4):416–425. DOI:10.4103/2229-5178.142483
Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002;47(5):789–791. DOI:10.1067/mjd.2002.124697
Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: A comprehensive overview. Part II: Treatment options and approach to treatment. J Am Acad Dermatol. 2011;65(3):493–514. DOI:10.1016/j.jaad.2010.11.062
Tran C, Lubbe J, Sorg O, et al. Topical calcineurin inhibitors decrease UVB-induced damage. Dermatology. 2005;211(4):341–347. DOI:10.1159/000088498
Silpa-Archa N, Likittanasombat S, Apinuntham C, et al. The efficacy of bimatoprost with NB-UVB in vitiligo. Sci Rep. 2023;13(1):6438. DOI:10.1038/s41598-023-33788-7
Jha AK, Sinha R, Prasad S, et al. Bimatoprost in periorbital vitiligo. J Eur Acad Dermatol Venereol. 2016;30(7):1247–1248. DOI:10.1111/jdv.13105
Kanokrungsee S, Pruettivorawongse D, Rajatanavin N. Clinical outcomes of topical bimatoprost in facial vitiligo. J Cosmet Dermatol. 2021;20(3):812–818. DOI:10.1111/jocd.13664
Pruettivorawongse D, Kanokrungsee S, Ratchatanawin N. Comparison of bimatoprost and tacrolimus in vitiligo. J Am Acad Dermatol. 2018;79(3):AB82.
Kumari A, Kumar A, Manohar M, et al. Comparison of tacrolimus versus bimatoprost in vitiligo. Int J Pharm Sci Rev Res. 2024;84(10):37–41.
Zaky MS, Atallah RB, El Abasy NTA, et al. Comparative study of excimer light with tacrolimus versus bimatoprost. Arch Dermatol Res. 2024;316(7):350. DOI:10.1007/s00403-024-02926-2
Das SK, Majumder PP, Chakraborty R, et al. Epidemiological profile of vitiligo in India. Genet Epidemiol. 1985;2(1):71–78. DOI:10.1002/gepi.1370020109
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Riya Kalawat, Kshitij Saxena, Reyan Abdul Jamil, Dilshad Ali Rizvi, Ketki, Bhavika Bansal, Amarjeet Singh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
